Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25208089 | 0.99 | MAPT (0.62) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18053948 | 0.89 | MAPT (0.70) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29514975 | 0.86 | MAPT (0.58) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24322057 | 0.86 | MAPT (0.58) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18053871 | 0.84 | POLB (0.68) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17055159 | 0.83 | MAPT (0.62) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL20150158 | 0.83 | POLB (0.75) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17054792 | 0.82 | MAPT (0.68) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17054917 | 0.82 | MAPT (0.68) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1392957 | 0.81 | MAPT (0.72) | MAPTPOLBCHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | MAPT 2978/4885POLB 2788/4885CHRNB2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.